alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          SEP-30-1997
<PERIOD-START>                             OCT-01-1996
<PERIOD-END>                               SEP-30-1997
<CASH>                                          79,594
<SECURITIES>                                         0
<RECEIVABLES>                                   10,685
<ALLOWANCES>                                     4,325
<INVENTORY>                                      1,079
<CURRENT-ASSETS>                                98,315
<PP&E>                                          13,261
<DEPRECIATION>                                   5,222
<TOTAL-ASSETS>                                 109,215
<CURRENT-LIABILITIES>                           32,387
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        52,258
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                   109,215
<SALES>                                         99,515
<TOTAL-REVENUES>                                99,515
<CGS>                                           10,579
<TOTAL-COSTS>                                   10,579
<OTHER-EXPENSES>                                71,861
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                  50
<INCOME-PRETAX>                                 20,423
<INCOME-TAX>                                     5,310
<INCOME-CONTINUING>                             15,113
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    15,113
<EPS-PRIMARY>                                    $0.50
<EPS-DILUTED>                                    $0.50
        

</TABLE>
<PAGE>

                                                                    EXHIBIT 32.2

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

                  In connection with the Annual Report of Day International
Group, Inc. (the "Company") on Form 10-K for the period ending December 31, 2003
as filed with the Securities and Exchange Commission on the date hereof (the
"Report"), I, Thomas J. Koenig, Chief Financial Officer of the Company, certify,
pursuant to 18 U.S.C. Section 1350, as adopteD pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that to my knowledge:

                  (1)      The Report fully complies with the requirements of
Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

                  (2)      The information contained in the Report fairly
presents, in all material respects, the financial position and results of
operations of the Company.

                  A signed original of this written statement required by
Section 906, or other document authenticating, acknowledging, or otherwise
adopting the signature that appears in typed form within the electronic version
of this statement required by Section 906, has been provided to the Company and
will be retained by the Company and furnished to the Securities and Exchange
Commission or its staff upon request.

/s/ Thomas J. Koenig
------------------------------
Thomas J. Koenig
Chief Financial Officer
March 24, 2004
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7576 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7576

 To amend section 6323 of title 5, United States Code, to increase the 
rate at which military leave accrues for members of the Reserve and the 
    National Guard from 15 days to 30 days per year, and for other 
                               purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 7, 2024

  Mr. Van Orden (for himself and Mr. Pappas) introduced the following 
      bill; which was referred to the Committee on Oversight and 
                             Accountability

_______________________________________________________________________

                                 A BILL

 
 To amend section 6323 of title 5, United States Code, to increase the 
rate at which military leave accrues for members of the Reserve and the 
    National Guard from 15 days to 30 days per year, and for other 
                               purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Reserve and National Guard Military 
Leave Enhancement Act''.

SEC. 2. INCREASE IN LEAVE ACCRUAL FOR MILITARY SERVICE OF CERTAIN 
              FEDERAL EMPLOYEES.

    Section 6323(a)(1) of title 5, United States Code, is amended--
            (1) by striking ``15 days per fiscal year'' and inserting 
        ``30 days per fiscal year''; and
            (2) by striking ``until it totals 15 days at the beginning 
        of a fiscal year''.
                                 <all>
```
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.1 Scope. ( a ) This part sets forth the classification of hematology and pathology devices intended for human use that are in commercial distribution.
( b ) The identification of a device in a regulation in this part is not a precise description of every device that is, or will be, subject to the regulation. A manufacturer who submits a premarket notification submission for a device under part 807 may not show merely that the device is accurately described by the section title and identification provisions of a regulation in this part, but shall state why the device is substantially equivalent to other devices, as required by § 807.87.
( c ) References in this part to regulatory sections of the Code of Federal Regulations are to chapter I of title 21, unless otherwise noted.
( d ) Guidance documents referenced in this part are available on the Internet at *http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/default.htm .*
[52 FR 17732, May 11, 1987, as amended at 69 FR 12273, Mar. 16, 2004; 78 FR 18233, Mar. 26, 2013; 79 FR 50552, Aug. 25, 2014]
§ 82.1051 Lakes (D&C). ( a ) ( 1 ) *General.* Any lake, other than those listed in subpart B, made by extending on a substratum of alumina, blanc fixe, gloss white, clay, titanium dioxide, zinc oxide, talc, rosin, aluminum benzoate, calcium carbonate, or any combination of two or more of these, ( i ) one of the straight colors (except lakes) listed in subpart B or hereinbefore listed in this subpart, which color is a salt in which is combined the basic radical sodium, potassium, aluminum, barium, calcium, strontium, or zirconium; or
( ii ) a salt prepared from one of the straight colors (except lakes) listed in subpart B, or hereinbefore listed in this subpart, by combining such color with the basic radical sodium, potassium, aluminum, barium, calcium, strontium, or zirconium.
( 2 ) *Specifications.* Ether extracts, not more than 0.5 percent. Soluble chlorides and sulfates (as sodium salts), not more than 3.0 percent. Intermediates, not more than 0.2 percent.
( b ) Each lake made as prescribed in paragraph (a) of this section shall be considered to be a straight color and to be listed therein under the name which is formed as follows: ( 1 ) The listed name of the color from which the lake is prepared, except that if such name contains the symbol “FD&C” such symbol shall be changed to “D&C”;
( 2 ) The name of the basic radical combined in such color; and
( 3 ) The word “Lake.”
(For example, the name of a lake prepared by extending the color D&C Red No. 9 upon a substratum is “D&C Red No. 9—Barium Lake”, and a lake prepared by extending the aluminum salt prepared from FD&C Green No. 1 upon a substratum other than alumina is “D&C Green No. 1—Aluminum Lake”.)
§ 809.40 Restrictions on the sale, distribution, and use of OTC test sample collection systems for drugs of abuse testing. ( a ) Over-the-counter (OTC) test sample collection systems for drugs of abuse testing (§ 864.3260 of this chapter) are restricted devices under section 520(e) of the Act subject to the restrictions set forth in this section.
( b ) Sample testing shall be performed in a laboratory using screening tests that have been approved, cleared, or otherwise recognized by the Food and Drug Administration as accurate and reliable for the testing of such specimens for identifying drugs of abuse or their metabolites.
( c ) The laboratory performing the test(s) shall have, and shall be recognized as having, adequate capability to reliably perform the necessary screening and confirmatory tests, including adequate capability to perform integrity checks of the biological specimens for possible adulteration.
( d ) All OTC test sample collection systems for drugs of abuse testing shall be labeled in accordance with § 809.10(f) and shall provide an adequate system to communicate the proper interpretation of test results from the laboratory to the lay purchaser.
[65 FR 18234, Apr. 7, 2000]
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### National Archives and Records Administration

###### Information Security Oversight Office

          - 32 CFR Part 2004
          - [NARA-09-0005]
          - RIN 3095-AB34

# AGENCY:

Information Security Oversight Office, NARA.

# ACTION:

Proposed rule; correction.

# SUMMARY:

                        This document corrects the heading to a proposed rule published in the                         **Federal Register**                         of November 30, 2009, regarding the National Industrial Security Program Directive No. 1. This correction assigns a Federal Docket Management System (FDMS) number to the proposed rule for Information Security Oversight Office (ISOO) regulations and provides a new regulation identifier number (RIN).                    

# FOR FURTHER INFORMATION CONTACT:

Laura McCarthy, 301-837-3023.

# SUPPLEMENTARY INFORMATION:

In proposed rule FR Doc. E9-28517, beginning on page 62531 in the issue of November 30, 2009, make the following corrections in the heading of the document.

## Correction

On page 62531, correct the docket number to read “[ISOO-09-0001]”and correct the RIN to read “3095-AB63”.

Dated: January 5, 2010.

Laura J. McCarthy,

Federal Register Liaison.

[FR Doc. 2010-394 Filed 1-11-10; 8:45 am]

BILLING CODE 7515-01-P
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 18-1244

REDMOND HOWARD,

Plaintiff - Appellant,

v.

EDWARD RUSSO; JORDAN GEIBEL; SCOTT HAMILTON,

Defendants - Appellees,

and

JEFFREY FLOYD; KAREN FLOYD; JONATHAN SCHMEDEL,

Defendants.

Appeal from the United States District Court for the District of Maryland, at Baltimore. 

George L. Russell, III, District Judge. (1:16-cv-03948-GLR)

Submitted: May 24, 2018 Decided: May 30, 2018

Before NIEMEYER, MOTZ, and FLOYD, Circuit Judges.

Dismissed by unpublished per curiam opinion.

Redmond Howard, Appellant Pro Se. Jordan Geibel, Appellee Pro Se.

Unpublished opinions are not binding precedent in this circuit.
2

PER CURIAM:

Redmond Howard seeks to appeal the district court’s order addressing the various 

motions Howard filed in a pending civil suit. This court may exercise jurisdiction only 

over final orders, 28 U.S.C. § 1291 (2012), and certain interlocutory and collateral orders, 

28 U.S.C. § 1292 (2012); Fed. R. Civ. P. 54(b); Cohen v. Beneficial Indus. Loan Corp., 

337 U.S. 541, 545-46 (1949). The order Howard seeks to appeal is neither a final order 

nor an appealable interlocutory or collateral order. Accordingly, we dismiss the appeal 

for lack of jurisdiction. We dispense with oral argument because the facts and legal 

contentions are adequately presented in the materials before this court and argument 

would not aid the decisional process.

DISMISSED
§ 250.100 Amyl nitrite inhalant as a prescription drug for human use. ( a ) Amyl nitrite inhalant has been available over-the-counter for emergency use by the patient in the management of angina pectoris for a number of years. As a result of a proposed policy statement published August 25, 1967 (32 FR 12404), the Commissioner of Food and Drugs received reports of the abuse of this drug by those who do not require it for medical purposes. Additionally, comment included a great deal of concern expressed by individual physicians, medical associations, pharmaceutical associations, manufacturers, and State and local health authorities. Based on the information available, it is the opinion of the Commissioner of Food and Drugs, concurred in by the Food and Drug Administration Medical Advisory Board, that amyl nitrite inhalant is a drug with a potentiality for harmful effect and that it should be removed from over-the-counter status and restricted to sale on the prescription of a practitioner licensed by law to administer such drug.
( b ) Therefore, amyl nitrite inhalant will be regarded as misbranded unless the labeling on or within the package from which the drug is to be dispensed bears adequate information for its safe and effective use by physicians, in accordance with § 201.100(c) of this chapter, and its label bears the statement “Rx only.”
( c ) Regulatory proceedings may be initiated with regard to the interstate shipment of amyl nitrite inhalant that is labeled, advertised, or dispensed contrary to this statement of policy if such act occurs after July 1, 1969.
[40 FR 14033, Mar. 27, 1975, as amended at 67 FR 4906, Feb. 1, 2002]
<PAGE>   1
                                                                    EXHIBIT 11.3

                             WEBLINK WIRELESS, INC.
                    COMPUTATION OF PER SHARE EARNINGS (LOSS)
<TABLE>
<CAPTION>
                                                     TWELVE MONTHS ENDED DECEMBER 31, 1999
                                                  -------------------------------------------
                                                     NUMBER       PERCENT        EQUIVALENT
                                                    OF SHARES    OUTSTANDING       SHARES
                                                  ------------   -----------    ------------
<S>                                               <C>            <C>            <C>
COMMON STOCK
   From Founders' Stock                              2,300,000      100.00%        2,300,000
   Stock Options Exercised                           1,316,931       85.05%        1,120,066
   Preferred Stock Converted to Common Stock        15,310,943      100.00%       15,310,943
   1994 Common Stock Offerings                      11,242,857      100.00%       11,242,857
   1995 Common Stock Offerings                       4,323,874      100.00%        4,323,874
   1996 Common Stock Offering                        6,000,000      100.00%        6,000,000
   1999 Treasury Stock Transaction                      (6,588)      10.96%             (722)
   Employee Stock Purchase Plan Shares Issued          145,737       81.88%          119,333
   Warrants Exercised                                  130,513       63.75%           83,208
                                                  ------------                  ------------
                                                    40,764,267                    40,499,559

WEIGHTED AVERAGE SHARES OUTSTANDING                                               40,499,559

NET LOSS                                                                        $(99,866,909)

NET LOSS PER SHARE                                                              $      (2.47)
                                                                                ============
</TABLE>
<PAGE>

                                                                    EXHIBIT 32.2

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Evergreen Solar, Inc. (the "Company") on
Form 10-K for the year ended December 31, 2003 as filed with the Securities and
Exchange Commission on the date hereof (the "Report"), I, Richard G. Chleboski,
Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C.
Section1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, that to my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material
respects, the financial condition and result of operations of the Company.

/s/ Richard G. Chleboski
-------------------------
Richard G. Chleboski
Chief Financial Officer
March 23, 2004
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1914 Trypsin. ( a ) Trypsin (CAS Reg. No. 9002-07-7) is an enzyme preparation obtained from purified extracts of porcine or bovine pancreas. It is a white to tan amorphous powder. Its characterizing enzyme activity is that of a peptide hydrolase (EC 3.4.21.4).
( b ) The ingredient meets the general requirements and additional requirements for enzyme preparations in the Food Chemicals Codex, 3d ed. (1981), p. 110, which is incorporated by reference in accordance with 5 U.S.C. 552(a) and 1 CFR part 51. Copies are available from the National Academy Press, 2101 Constitution Ave. NW., Washington, DC 20418, or may be examined at the Office of Food Additive Safety (HFS-200), Center for Food Safety and Applied Nutrition, Food and Drug Administration, 5001 Campus Dr., College Park, MD 20740, 240-402-1200, and at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) In accordance with § 184.1(b)(1), the ingredient is used in food with no limitation other than current good manufacturing practice. The affirmation of this ingredient as GRAS as a direct food ingredient is based upon the following current good manufacturing practice conditions of use: ( 1 ) The ingredient is used as an enzyme as defined in § 170.3(o)(9) of this chapter to hydrolyze proteins or polypeptides.
( 2 ) The ingredient is used in food at levels not to exceed current good manufacturing practice.
[60 FR 32911, June 26, 1995, as amended at 78 FR 14667, Mar. 7, 2013]
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from IDS Managed
Futures II, L.P. for the third quarter of 1998 and is qualified in its entirety
by reference to such 10-Q.
</LEGEND>
<CIK> 0000813831
<NAME> IDS MANAGED FUTURES II, L.P.
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-END>                               SEP-30-1998
<CASH>                                      13,014,698
<SECURITIES>                                         0
<RECEIVABLES>                                   35,787
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                            13,050,485
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                              13,050,485
<CURRENT-LIABILITIES>                          355,610
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                  12,694,876
<TOTAL-LIABILITY-AND-EQUITY>                13,050,485
<SALES>                                              0
<TOTAL-REVENUES>                             2,777,411
<CGS>                                                0
<TOTAL-COSTS>                                  377,715
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                              2,399,696
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                          2,399,696
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 2,399,696
<EPS-PRIMARY>                                   133.73
<EPS-DILUTED>                                   133.73
        

</TABLE>